Abstract
Background and objectives: BRONJ is characterized by a chronic soft tissue wound and bone necrosis exclusive to the jaws of a fraction of patients taking bishosphonates. Oral bishosphonates are used in the treatment of osteoporosis and Paget's disease, where as injectable ones are used in the hypercalcemia of malignancy. BRONJ is seen in 5–10% of cancer patients taking bishosphonates. Pathogenesis of the disease, various conservative and surgical treatment modalities are under investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Oral & Maxillofacial Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
